Rituxan (rituximab) - Roche
cyclophosphamide - Generic mfg.
Inflammatory and Autoimmune Axonal Neuropathies. (PubMed, Continuum (Minneap Minn)) - Oct 3, 2026 - "Recent studies highlight the role of serum neurofilament light chain as a biomarker of the rate of active axonal injury and the increasing use of rituximab over cyclophosphamide for induction in neutrophil cytoplasmic antibody-associated vasculitis. Treatment focuses on halting inflammation and preventing relapses, with corticosteroids as first-line induction and steroid-sparing agents for maintenance. A structured follow-up approach, including standardized neurologic examinations, functional assessments, and ancillary testing, is essential for tracking disease progression and treatment response." 
IO biomarker • Journal • Review • Ataxia • Immunology • Inflammation • Movement Disorders • Pain • Vasculitis • NEFL
http://www.ncbi.nlm.nih.gov/pubmed/42825555
 
Qihua Fan; Vinay Chaudhry
 
Oct 3, 2026
 
Prev Next